Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Project Oncology®
A Patient-First Approach to Smoking Cessation and Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
- Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
The Importance of Multidisciplinary Coordination in NSCLC Care
The Importance of Multidisciplinary Coordination in NSCLC Care
Project Oncology®
The Importance of Multidisciplinary Coordination in NSCLC Care
Laura Alder, MD
- Laura Alder, MD
Improving Adherence and Toxicity Monitoring in NSCLC Care
Improving Adherence and Toxicity Monitoring in NSCLC Care
Project Oncology®
Improving Adherence and Toxicity Monitoring in NSCLC Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Project Oncology®
Innovations Shaping the Future of Antibody-Drug Conjugates in NSCLC
Christine Bestvina, MD
- Christine Bestvina, MD
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Project Oncology®
Key Questions Shaping Antibody-Drug Conjugate Use in NSCLC
Laura Alder, MD
- Laura Alder, MD
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Project Oncology®
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Christine Bestvina, MD
- Christine Bestvina, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
- Laura Alder, MD

Medical News

Medical News
Stepped Reminders Boost Lung Cancer Screening Adherence
09/17/2026
Read more
Medical News
Blood mRNA Panel May Detect Early Pancreatic Cancer
09/17/2026
Read more
Medical News
AI Tracks Colorectal Liver Metastases on Follow-up CT
09/17/2026
Read more
Medical News
Sugarbaker Mesh Lowers Parastomal Hernia After APR
09/17/2026
Read more

CME/CE

CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits

Clinical Practice

Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Oncology and Hematology
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Byoung Chul Cho, MD, PhD
- Byoung Chul Cho, MD, PhD
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Project Oncology®
Tobacco-Related Stigma as a Barrier to Lung Cancer Screening
Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
- Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN, FSBM
Smarter Screening for Non-Small Cell Lung Cancer
Smarter Screening for Non-Small Cell Lung Cancer
Project Oncology®
Smarter Screening for Non-Small Cell Lung Cancer
Jobelle Baldonado, MD
- Jobelle Baldonado, MD
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Project Oncology®
Managing Antibody-Drug Conjugate Toxicities in NSCLC Care
Laura Alder, MD
- Laura Alder, MD

Programs

A New Era of Hope in Non-Small Cell Lung Cancer Care
A New Era of Hope in Non-Small Cell Lung Cancer Care
Project Oncology®
A New Era of Hope in Non-Small Cell Lung Cancer Care
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Project Oncology®
The Evolving Role of Antibody-Drug Conjugates in NSCLC Care
Raghava Reddy Induru, MD
- Raghava Reddy Induru, MD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 29, 2026
12:00 PM - 01:00 PM EDT
1.00 credit
What's Next for Urothelial Cancer Treatment?
What's Next for Urothelial Cancer Treatment?
Project Oncology®
What's Next for Urothelial Cancer Treatment?
Benjamin Garmezy, MD
- Benjamin Garmezy, MD